Sanofi SA
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
82,878
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,756.60 | 39.40 | -0.45% |
| CAC 40 | 7,765.11 | 10.79 | -0.14% |
| DAX 40 | 23,771.45 | 177.45 | -0.74% |
| Dow JONES (US) | 42,967.62 | 101.85 | 0.24% |
| FTSE 100 | 8,884.92 | 20.57 | 0.23% |
| HKSE | 23,866.86 | 168.52 | -0.70% |
| NASDAQ | 19,662.48 | 46.61 | 0.24% |
| Nikkei 225 | 37,689.16 | 483.93 | -1.27% |
| NZX 50 Index | 12,526.07 | 123.03 | -0.97% |
| S&P 500 | 6,045.26 | 23.02 | 0.38% |
| S&P/ASX 200 | 8,533.90 | 31.20 | -0.36% |
| SSE Composite Index | 3,378.01 | 24.64 | -0.72% |